** Shares of Caribou Biosciences CRBU.O rise 3% to 89 cents in extended trading
** Co says it is reducing workforce by 32% to extend its cash runway into H2 of 2027; as of March 31, co had about $212.5 mln in cash
** CRBU had 147 full-time employees as of March 1 - SEC filing
** Co says it will prioritize two cancer therapy programs, CB-010 and CB-011
** Also says it is stopping work on lupus and leukemia treatment trials
** As of last close, stock down 45% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。